Inversiones e implantacionesSalud - Farma - Biotecnología
Inside Information / Other news releases
19/11/2026 18:28
AMFPublicación inmediata
Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates
W ORL D P AN CRE AT IC C A NCER D AY · NO VEMBER 19 , 20 26
Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates
Centro Médico Teknon in Barcelona, a flagship of Spain's leading private hospital group
Quirónsalud now offers enhanced characterization of pancreatic cysts with Cellvizio
King's College Hospital London in Dubai is the first hospital in the MENA region to offer
Cellvizio for improved detection of early pancreatic cancer
These two key installations mark World Pancreatic Cancer Day, addressing one of the world's deadliest cancers, causing nearly 490,000 deaths1 annually
Paris and Boston, November 19, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the clinical deployment of Cellvizio® for improved pancreatic cyst characterization at two flagship institutions: Centro Médico Teknon in Barcelona, the first hospital in Spain, and King's College Hospital London in Dubai, the first hospital in the Middle East and North Africa (MENA) region, marking World Pancreatic Cancer Day.
As the sixth leading cause of cancer mortality worldwide, with an estimated 531,000 new cases and nearly 490,000 deaths annually1, pancreatic cancer carries a five-year survival rate below 10%2, making quick characterization of pancreatic cystic lesions critical. Although CT and MRI scans incidentally detect pancreatic cysts in 3% to 10% of adults3 (and 10% to 20% over age 704), conventional work-up often falls short: up to 30% of cysts remain indeterminate after endoscopic ultrasound5 and over 50% of fine-needle cytology aspirations are inconclusive6. Consequently, 40% to 78% of pancreatic resections, high-risk major surgeries, are performed unnecessarily on benign cysts, while other patients undergo unnecessary lifelong surveillance7.
Included in the European Society of Gastrointestinal Endoscopy (ESGE) guidelines8, EUS-nCLE with Cellvizio® resolves this impasse by allowing the endoscopist to pass a microscopic optical probe through the puncture 1 World Health Organization (WHO) / International Agency for Research on Cancer (IARC), Global Cancer Observatory, GLOBOCAN 2024 Pancreas Fact Sheet; World Pancreatic Cancer Coalition, World Pancreatic Cancer Day.
2 OMS / CIRC, World Cancer Report ; registres SEER et NPCR, 2025 (taux de survie globale à cinq ans inférieur à 10 %). 3 Laffan TA et al., Prevalence of unsuspected pancreatic cysts on MDCT, American Journal of Roentgenology, 2008;191(3):802,807; Lee KS et al., Prevalence of incidental pancreatic cysts in the adult population on MR imaging, American Journal of Gastroenterology, 2010;105(9):2079,2084. 4 Laffan TA et al., Prevalence of unsuspected pancreatic cysts on MDCT, American Journal of Roentgenology, 2008;191(3):802,807; Lee KS et al., Prevalence of incidental pancreatic cysts in the adult population on MR imaging, American Journal of Gastroenterology, 2010;105(9):2079,2084. 5 Rodríguez-D'Jesús A. et al., Impact of endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration on the management of pancreatic cystic lesions, European Journal of Gastroenterology & Hepatology, 2016;28(9):1094,1099.